Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Durlobactam (DUR; ETX2514) is a novel β-lactamase inhibitor with broad-spectrum activity against Ambler class A, C, and D β-lactamases. Durlobactam restores the in vitro activity of sulbactam (SUL) against members of the Acinetobacter baumannii-A. calcoaceticus complex (ABC). Sulbactam (SUL)-durloba...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Sagan, Olexiy, Yakubsevitch, Ruslan, Yanev, Krassimir, Fomkin, Roman, Stone, Emily, Hines, Daniel, O’Donnell, John, Miller, Alita, Isaacs, Robin, Srinivasan, Subasree
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2020
Assuntos:
Clinical Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7038258/
https://ncbi.nlm.nih.gov/pubmed/31843995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01506-19
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados